IVIG and SCIG products comparison

Immunoglobulin

Clinical comparison of all FDA-approved immunoglobulin products for providers. Compare concentration, IgA content, stabilizer, sugar content, osmolality, storage, FDA-approved indications, and compatibility considerations. Sources: FDA prescribing information.

Select any two to compare side by side

All products in this comparison

ProductManufacturerRouteFrequencyConcentrationIgA ContentStabilizerSugar ContentOsmolalitypHStorageFDA IndicationsContraindicationsCompatibility NotesGlucose MonitoringKey difference
PrivigenCSL BehringIVEvery 3–4 weeks10%≤25 mcg/mLL-prolineNone320 mOsmol/kg4.8Room temp (up to 36 months) or refrigeratedPIDD, CIDPIgA deficiency with anti-IgA antibodies; hyperprolinemia; severe hypersensitivityNo sucrose: preferred for renal risk patientsNo interference (no maltose)L-proline stabilized; very low IgA (≤25 mcg/mL); no sugar; FDA-approved for CIDP and PIDD
Gamunex-CGrifolsIV / SCEvery 3–4 weeks (IV) or weekly (SC)10%46 mcg/mL averageGlycine (caprylate/chromatography purified)None258 mOsmol/kg4.0–4.5Refrigerated; room temp up to 6 monthsPIDD, CIDP, ITPIgA deficiency with anti-IgA antibodies; hypersensitivityNo sucrose: preferred for renal risk patients; also approved for SC useNo interference (no maltose)Dual IV/SC route; caprylate-stabilized; approved for CIDP, PIDD, ITP
Gammagard LiquidTakedaIV / SCEvery 3–4 weeks (IV) or weekly (SC)10%37 mcg/mL averageGlycineNone240–300 mOsmol/kg4.6–5.1Refrigerated (up to 36 months); room temp up to 9 monthsPIDD (IV and SC), MMN (IV)IgA deficiency with anti-IgA antibodies; hypersensitivity; corn allergy (trace)Only IVIG with FDA-approved MMN indication; no sucroseNo interferenceDual IV/SC route; glycine-stabilized; 10% concentration
Gammagard S/DTakedaIVEvery 3–4 weeks5% or 10% (reconstituted)<1 mcg/mL (5%), lowest availableGlucose, glycine, PEGSUCROSE, renal risk636 mOsmol/kg (10%)6.4–7.2Room temperature (lyophilized)PIDD, ITP, Kawasaki, B-cell CLLIgA deficiency with anti-IgA antibodies; renal insufficiency (sucrose risk); hypersensitivity⚠️ Contains sucrose, avoid in renal impairment. Preferred for IgA-deficient patients (lowest IgA)No maltose interference but monitor renal functionLyophilized; lowest IgA option; 5% or 10%; CONTAINS SUCROSE
OctagamOctapharmaIVEvery 3–4 weeks5% and 10%≤200 mcg/mL (10%)Maltose (5%); no sugar (10%)5%: maltose; 10%: none310–380 mOsmol/kg5.1–6.0Refrigerated; room temp up to 18 months (10%)PIDD (5% and 10%), ITP (10%)IgA deficiency with anti-IgA antibodies; hypersensitivity⚠️ 5% contains maltose: can cause falsely elevated blood glucose readings with GDH-PQQ test strips. Use glucose-specific monitors only⚠️ 5%: maltose interferes with GDH-PQQ glucose tests5% and 10%; maltose-containing (5%); caution with glucose monitoring
GammaplexGrifolsIVEvery 3–4 weeks5% and 10%<10 mcg/mL (5%); ≤20 mcg/mL (10%)SorbitolNone420–520 mOsmol/kg4.8–5.1Refrigerated; room temp up to 24 months (10%)PIDD, ITPIgA deficiency with anti-IgA antibodies; hereditary fructose intolerance (contains sorbitol); hypersensitivity⚠️ Contains sorbitol: contraindicated in hereditary fructose intoleranceNo interference5% and 10%; sorbitol-stabilized; no sugar; approved for PIDD and ITP
PanzygaOctapharmaIVEvery 3–4 weeks10%≤100 mcg/mLGlycineNone240–310 mOsmol/kg4.5–5.0Refrigerated; room temp up to 24 monthsPIDD, ITPIgA deficiency with anti-IgA antibodies; hypersensitivityNo sucrose, no maltose: no special renal or glucose concernsNo interference10%; glycine-stabilized; approved for PIDD and ITP
BivigamADMA BiologicsIVEvery 3–4 weeks10%Not specified (traces)GlycineNone267–378 mOsmol/kg4.0–4.6RefrigeratedPIDDIgA deficiency with anti-IgA antibodies; hypersensitivityNo sucrose, no maltoseNo interference10% liquid; glycine-stabilized; approved for PIDD
AscenivADMA BiologicsIVEvery 3–4 weeks10%Not specified (traces)Glycine, polysorbate 80None270–390 mOsmol/kg4.5–4.9RefrigeratedPIDDIgA deficiency with anti-IgA antibodies; hypersensitivityUnique: standardized anti-pneumococcal antibody levels, may benefit recurrent infection patientsNo interferenceStandardized high-titer anti-pneumococcal antibodies; for PIDD patients with recurrent infections
Flebogamma DIFGrifolsIVEvery 3–4 weeks5% and 10%≤50 mcg/mLD-sorbitol (5%); none (10%)None240–370 mOsmol/kg5.0–6.0Room temperature up to 24 monthsPIDDIgA deficiency with anti-IgA antibodies; hypersensitivityRoom temp storage advantageNo interference5% and 10%; sorbitol-free (unlike Gammaplex); D-sorbitol–free formulation
GammakedGrifolsIV / SCEvery 3–4 weeks (IV) or weekly (SC)10%46 mcg/mL averageGlycineNone258 mOsmol/kg4.0–4.5Refrigerated; room temp up to 6 monthsPIDD, CIDP, ITPIgA deficiency with anti-IgA antibodies; hypersensitivityEssentially same product as Gamunex-C (different brand name/distributor)No interferenceDual IV/SC route; same formulation as Gamunex-C; approved for CIDP, PIDD, ITP
HizentraCSL BehringSCWeekly or biweekly20%≤50 mcg/mLL-prolineNone380 mOsmol/kg4.6–5.2Room temperature up to 30 monthsPIDD, CIDPIgA deficiency with anti-IgA antibodies; hyperprolinemia; hypersensitivity⚠️ Contains L-proline: contraindicated in hyperprolinemia. Preferred for home infusionNo interference20% SC; home self-infusion; L-proline stabilized; approved for PIDD and CIDP
HyQviaTakedaSC (facilitated)Monthly10% IG + hyaluronidase37 mcg/mL averageGlycine + hyaluronidase componentNone240–300 mOsmol/kg4.6–5.1RefrigeratedPIDDIgA deficiency with anti-IgA antibodies; hypersensitivity to hyaluronidaseOnly monthly SC option: significant convenience advantage. Hyaluronidase allows larger volume SC infusionNo interferenceMonthly SC dosing via recombinant hyaluronidase; approved for PIDD
CuvitruTakedaSCWeekly20%80 mcg/mL averageGlycineNone210–370 mOsmol/kg4.6–5.1Room temperature up to 24 monthsPIDDIgA deficiency with anti-IgA antibodies; hypersensitivityRoom temp storage; higher IgA than some alternatives. Check patient IgA statusNo interference20% SC; room temperature storage; approved for PIDD
CutaquigOctapharmaSCWeekly16.5%≤600 mcg/mLMaltose-freeNone310–380 mOsmol/kg5.0–5.5Refrigerated; room temp up to 6 monthsPIDDIgA deficiency with anti-IgA antibodies; hypersensitivity⚠️ Higher IgA content than other SC options. Verify patient IgA antibody statusNo interference16.5% SC; maltose-free; approved for PIDD
XembifyGrifolsSCWeekly20%≤10 mcg/mL, one of the lowest for SC productsGlycineNone240–300 mOsmol/kg4.1–4.8Refrigerated; room temp up to 12 monthsPIDDIgA deficiency with anti-IgA antibodies; hypersensitivityVery low IgA, preferred SC option for IgA-sensitive patientsNo interference20% SC; low IgA; approved for PIDD

Related guides

Clinical data sourced from FDA-approved prescribing information. Verify current product labeling before clinical decisions.

Denied one of these medications?

Ellen can decode your denial letter, identify why you were denied, and generate a personalized appeal, free for patients.